ArticleLeukemia2022
Sirolimus is effective for refractory/relapsed/intolerant acquired pure red cell aplasia: results of a prospective single-institutional trial.
Article in Leukemia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Treatment strategy for acquired pure red cell aplasia: a systematic review and meta-analysis.Blood advances · 2023Pooled it
- Sirolimus plus roxadustat synergistically enhances immunosuppression and erythropoiesis in pure red cell aplasia: a multicenter trial.Signal transduction and targeted therapy · 2026Trial
- Treatment-free survival to bortezomib combined with dexamethasone in patients with refractory/relapsed pure red cell aplasia: a prospective clinical study.Annals of medicine · 2025Trial
- Clinical heterogeneity and outcome of acquired PRCA: a multicenter European study.Blood advances · 2026Article
- Recurrent thymoma-associated PRCA with persistent agranulocytosis: a case report and therapeutic considerations.Frontiers in oncology · 2026Article
- Favorable response to second-line sirolimus regardless ofTherapeutic advances in hematology · 2026Article
- Pure Red Cell Aplasia Associated With Thymic Tumors, a Nationwide Retrospective Study.American journal of hematology · 2025Article
- Feline leukaemia virus (FeLV) infection in domestic pet cats in Australia and New Zealand: Guidelines for diagnosis, prevention and management.Australian veterinary journal · 2025Review
- Sirolimus modulates the erythroid differentiation of K562 cells by upregulating SHP1.Annals of hematology · 2025Article
- [Nonspecific peripheral T cell lymphoma combined with pure red cell aplasia: a case report and literature review].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Review
- Refractory pure red cell aplasia associated with T-cell large granular lymphocyte leukemia treated by ruxolitinib.Annals of hematology · 2024Article
- A nomogram model for predicting the efficacy of cyclosporine in patients with pure red cell aplasia.Annals of hematology · 2024Article
- Sirolimus versus cyclosporine A in patients with primary acquired pure red cell aplasia: a prospective cohort study.Blood cancer journal · 2023Article
- Sirolimus is effective for primary refractory/relapsed warm autoimmune haemolytic anaemia/Evans syndrome: a retrospective single-center study.Annals of medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Some patients with acquired pure red cell aplasia (aPRCA) have no response or are intolerant to cyclosporine A. From April 2017 to August 2020, patients diagnosed with aPRCA at Peking Union Medical College Hospital who were refractory/recurrent/intolerant to at least 6 months of full-dose cyclosporin A (CsA) with/without steroids were recruited and treated with sirolimus for at least 6 months. Finally, a total of 64 patients were enrolled. The overall response rate and complete response rate after 3, 6 and 12 months of sirolimus were 60.9%, 84.4%, and 73.5% and 50.0%, 65.6%, and 66.0%, respectively. At a median of 14.5 (6-47) months of follow-up, 14.8% (8/54) of the patients relapsed. Apart from haemoglobin improvement, patients had decreased creatine levels and serum ferritin levels at the end of the follow-up compared with the baseline (169.3 μmol/L vs. 146.4 μmol/L, p = 0.041; 2121.5 ng/mL vs. 1018.3 ng/mL, p = 0.013). Adverse events were recorded in 19 patients, including infections and increase of creatine. Secondary aPRCA with stable underlying diseases had similar results as those with primary aPRCA. In summary, sirolimus is effective for patients with refractory/recurrent/intolerant aRPCA with a low recurrence rate and toxicities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.